Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARC-101C in Autoimmune Type 1 Diabetes
NCT06546436Phase 1Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of CARC-101C in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Incidence and severity of adverse events at 21 days. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
CARC-101C
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06546436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546436.